1-7 of 7
Jonathan A. Pachter
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Duvelisib Eliminates CLL B Cells, Impairs CLL-Supporting Cells, and Overcomes Ibrutinib Resistance in a Xenograft Model

Shih-Shih Chen, Jacqueline C. Barrientos, Gerardo Ferrer, Morgan King-Richards, Yu-Ju Chen, Priyadarshini Ravichandran, Michael Ibrahim, Yasmine Kieso, Sheila Waters, Jeffery L. Kutok, Marisa Peluso, Sujata Sharma, David T. Weaver, Jonathan A. Pachter, Kanti R. Rai, Nicholas Chiorazzi
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (10): 1984–1995.
https://doi.org/10.1158/1078-0432.CCR-22-2386
Published: 15 May 2023
View article titled, Duvelisib Eliminates CLL B Cells, Impairs CLL-Supporting Cells, and Overcomes Ibrutinib Resistance in a Xenograft Model
Open the PDF for Duvelisib Eliminates CLL B Cells, Impairs CLL-Supporting Cells, and Overcomes Ibrutinib Resistance in a Xenograft Model in another window
Includes: Supplementary data
Journal Articles

Correction: Synthetic Lethal Screens Reveal Cotargeting FAK and MEK as a Multimodal Precision Therapy for GNAQ-Driven Uveal Melanoma

Justine S. Paradis, Monica Acosta, Robert Saddawi-Konefka, Ayush Kishore, Simone Lubrano, Frederico Gomes, Nadia Arang, Manoela Tiago, Silvia Coma, Xingyu Wu, Kyle Ford, Chi-Ping Day, Glenn Merlino, Prashant Mali, Jonathan A. Pachter, Takami Sato, Andrew E. Aplin, J. Silvio Gutkind
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (16): 4664.
https://doi.org/10.1158/1078-0432.CCR-21-2433
Published: 15 August 2021
View article titled, Correction: Synthetic Lethal Screens Reveal Cotargeting FAK and MEK as a Multimodal Precision Therapy for <em>GNAQ</em>-Driven Uveal Melanoma
Open the PDF for Correction: Synthetic Lethal Screens Reveal Cotargeting FAK and MEK as a Multimodal Precision Therapy for <em>GNAQ</em>-Driven Uveal Melanoma in another window
Journal Articles

Synthetic Lethal Screens Reveal Cotargeting FAK and MEK as a Multimodal Precision Therapy for GNAQ-Driven Uveal Melanoma

Justine S. Paradis, Monica Acosta, Robert Saddawi-Konefka, Ayush Kishore, Simone Lubrano, Frederico Gomes, Nadia Arang, Manoela Tiago, Silvia Coma, Xingyu Wu, Kyle Ford, Chi-Ping Day, Glenn Merlino, Prashant Mali, Jonathan A. Pachter, Takami Sato, Andrew E. Aplin, J. Silvio Gutkind
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (11): 3190–3200.
https://doi.org/10.1158/1078-0432.CCR-20-3363
Published: 01 June 2021
View article titled, Synthetic Lethal Screens Reveal Cotargeting FAK and MEK as a Multimodal Precision Therapy for <em>GNAQ</em>-Driven Uveal Melanoma
Open the PDF for Synthetic Lethal Screens Reveal Cotargeting FAK and MEK as a Multimodal Precision Therapy for <em>GNAQ</em>-Driven Uveal Melanoma in another window
Includes: Supplementary data
Journal Articles

Abstract A61: FAK activity sustains intrinsic and acquired ovarian cancer resistance to platinum chemotherapy

Carlos J. Díaz Osterman, Duygu Ozmadenci, Elizabeth G. Kleinschmidt, Kristin N. Taylor, Allison M. Barrie, Shulin Jiang, Lisa M. Bean, Florian J. Sulzmaier, Jian Li, Xiao Lei Chen, Guo Fu, Marjaana Ojalill, Pekka Rappu, Jyrki Heino, Adam A. Mark, Guorong Xu, Kathleen M. Fisch, David T. Weaver, Jonathan A. Pachter, Balázs Győrffy, Michael T. McHale, Denise C. Connolly, Alfredo Molinolo, Dwayne G. Stupack, David D. Schlaepfer
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (13_Supplement): A61.
https://doi.org/10.1158/1557-3265.OVCA19-A61
Published: 01 July 2020
View article titled, Abstract A61: FAK activity sustains intrinsic and acquired ovarian cancer resistance to platinum chemotherapy
Journal Articles

Abstract NTOC-106: FAK INHIBITION RE–SENSITIZES PLATINUM–RESISTANT SEROUS OVARIAN CANCER

Lisa M. Bean, Florian J. Sulzmaier, Kristen M. Anderson, Isabelle Tancioni, Cheyenne R. Butcher, Sean Uryu, Christine Jean, Christine Lawson, Xiao Lei Chen, Elizabeth G. Kleinschmidt, Vihren N. Kolev, Jonathan A. Pachter, Dwayne G. Stupack, David D. Schlaepfer
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (11_Supplement): NTOC-106.
https://doi.org/10.1158/1557-3265.OVCASYMP16-NTOC-106
Published: 31 May 2017
View article titled, Abstract NTOC-106: FAK INHIBITION RE–SENSITIZES PLATINUM–RESISTANT SEROUS OVARIAN CANCER
Journal Articles

Abstract B13: Predictive biomarkers for FAK inhibitor sensitivity in ovarian cancer

Irina M. Shapiro, Christian M. Vidal, Vihren N. Kolev, David T. Weaver, Jonathan A. Pachter
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (19_Supplement): B13.
https://doi.org/10.1158/1078-0432.OVCA13-B13
Published: 13 May 2014
View article titled, Abstract B13: Predictive biomarkers for FAK inhibitor sensitivity in ovarian cancer
Journal Articles

Abstract A39: FAK inhibitors VS-6063 and VS-4718 preferentially target ovarian cancer stem cells

Vihren N. Kolev, Quentin G. Wright, Christian M. Vidal, Winnie F. Tam, Mahesh V. Pavdal, Qunli Xu, Jonathan A. Pachter
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (19_Supplement): A39.
https://doi.org/10.1158/1078-0432.OVCA13-A39
Published: 13 May 2014
View article titled, Abstract A39: FAK inhibitors VS-6063 and VS-4718 preferentially target ovarian cancer stem cells